University Children's Hospital University Medical Centre Ljubljana
Welcome,         Profile    Billing    Logout  
 1 Trial 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Osredkar, Damjan
MIS51ON, NCT03992430 / 2018-001762-42: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD)

Active, not recruiting
3
160
Europe, US, RoW
Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS
Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc.
Muscular Dystrophy, Duchenne
10/26
10/26
HemPhar, NCT04634136: Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy

Completed
N/A
55
Europe
Lab tests, Basic hematology and biochemistry, ECG, Cannabinoid Levels, Pharmacokinetics of cannabinoids, Full-spectrum Medical Canabis Product (HemPhar), Active substance, Placebo, Spasticity level according to modified Ashworth scale (Bohannon), Gross Motor Function Measure, Borg rating of perceived exertion scale, Edmonton symptom assessment system
University Medical Centre Ljubljana, PharmaHemp, University of Ljubljana, Faculty of Medicine
Children, Adult, Spastic Cerebral Palsy, Quality of Life, Cannabis, Physical Disability
12/23
02/24

Download Options